Product news from the 11/04/05 News Brief

Share this article:

Novartis announced the FDA's approval of Exjade (deferasirox), a once-daily oral iron chelator designed to treat chronic iron overload due to blood transfusions in adults and children ages two and older.

Roche's Tarceva (erlotinib), has won FDA approval for treatment of advanced pancreatic cancer.

Savient Pharmaceuticals announced the FDA approval of its New Drug Application for Soltamox (tamoxifen oral solution) for the treatment of breast cancer in adjuvant and metastatic settings and to reduce risks of breast cancer in women with ductal carcinoma in situ (DCIS) and reduction of breast cancer incidence in women with high risk of breast cancer. Soltamox is the product of Savient's wholly owned subsidiary, Rosemont Pharmaceuticals Ltd., located in the U.K.

GlaxoSmithKline announced that the FDA has approved Arranon (nelarabine) Injection, a chemotherapy agent for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and Tcell lymphoblastic lymphoma (TLBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

Share this article:

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.